Ofatumumab is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Ofatumumab becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about SaveRxCanada.to
List of countries where we can ship Ofatumumab:
Latest news releases on Ofatumumab:
Ofatumumab (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation.
Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops.
Physician reviewed ofatumumab patient information - includes ofatumumab description, dosage and directions.
Discover ARZERRA® (ofatumumab), approved for 4 CLL treatment indications. Find dosing information & patient resources. See Important Safety Information & BOXED WARNING.
Ofatumumab (Arzerra) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of chronic lymphocytic leukemia (CLL)
The active substance in Arzerra, ofatumumab, is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise ...
Ofatumumab (Arzerra) is an approved leukemia treatment marketed by Novartis and now in Phase 3 clinical tests for relapsing MS.
Ofatumumab er rettet mod det transmembrane differentieringsantigen CD20, som findes på normale og maligne B-celler. Binding af antistoffet til CD20 medfører ...
Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
Den schweiziske gigant Novartis overtog for et par år siden rettighederne til Genmabs ofatumumab i en handel, der potentielt kan passere langt over 1 mia. dollars.